Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education

American Journal of Pharmaceutical Education

Volumn 74, Issue 9, 2010, Pages

  Plevin, David M ^a   Ward, Helena M ^b   Ward, Michael B ^a   Sorich, Michael J ^a   Mckinnon, Ross A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Cancer; Genomic medicine; Monoclonal antibody; Pharmacodiagnostics; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; AUSTRALIA; DRUG DELIVERY SYSTEM; EDUCATION; HUMAN; INFORMATION PROCESSING; METHODOLOGY; NEOPLASM; NEW ZEALAND; ORGANIZATION AND MANAGEMENT; PHARMACIST; PHARMACY; PROFESSIONAL STANDARD;

ANTINEOPLASTIC AGENTS; AUSTRALIA; DATA COLLECTION; DRUG DELIVERY SYSTEMS; EDUCATION, PHARMACY; HUMANS; NEOPLASMS; NEW ZEALAND; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE;

EID: 79251508330     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/aj7409168     Document Type: Article

References (35)

1. Hall WD, Ward R, Liauw WS, Brien J-E, Lu CY. Tailoring access to high cost, genetically targeted drugs. Med J Aust. 2005;182(12):607-608.
2. Jørgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies: a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist. 2007;12(4):397-405.
3. Pearson S, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: Trastuzumab use in Australia - monitoring the effect of an expensive medicine access program. J Clin Oncol. 2007; 25(24):3688-693.
4. Pharmacogenomics: a primer for policymakers, National Health Policy Forum. http://www.nhpf.org/library/background-papers/BP_Pharmacogenomics_01-28-08.pdf. Accessed August 30, 2010.
5. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels, Food and Drug Administration. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed August 30, 2010.
6. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77(2):148-154.
7. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutationtargeted cancer therapies. Nat Biotechnol. 2006;24(8):985-995.
8. Brown MP, Buckley MF, Rudzki Z, Olver IN. Why we will need to learn new skills to control cancer. Intern Med J. 2007;37(3):201-204.
9. Ritchie J, Spencer L, O'Connor W. Carrying out qualitative analysis. In: Ritchie J, Lewis J, eds. Qualitative research practice - a guide for social science students and researchers. London: SAGE Publications; 2003: 219-260.
10. Haddy CA, Ward HM, Angley MT, McKinnon RA. Consumers' views of harmacogenetics - a qualitative study. Res Social Admin Pharm. 2009;6(3):221-231.
11. Corkindale D, Ward H, McKinnon R. Low adoption of pharmacogenetic testing: An exploration and explanation of the reasons in Australia. Personalized Med. 2007;4(2):191-199.
12. Latif DA, McKay AB. Pharmacogenetics and pharmacogenomics instruction in colleges and schools of pharmacy in the United States. Am J Pharm Educ 2005;69(2):152-156.
13. Zdanowicz MM, Huston SA, Weston GS. Pharmacogenomics in the professional pharmacy curriculum: Content, presentation and importance. Int J Pharm Educ. 2006;2(Fall):1-12.
14. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 2005;5(4):221-225.
15. Jones S. Pharmacy practice issues with targeted therapy for lung cancer. Am J Health-Syst Pharm 2003;60(24, Suppl 9):S11-S15
16. Gale DM. Molecular targets in cancer therapy. Semin Oncol Nurs. 2003;19(3):193-205.
17. Finley RS. Targeted therapy for lung cancer: implications for pharmacy practice. introduction. Am J Health-Syst Pharm 2003;60(24, Suppl. 9):S2-S3.
18. Viele CS. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health-Syst Pharm. 2007;64(9 Suppl 5):S25-S32.
19. Winkeljohn DL. Oral chemotherapy medications: the need for a nurse's touch. Clin J Oncol Nurs. 2007;11(6):793-6.
20. Faithfull S, Deery P. Implementation of capecitabine (Xeloda®) into a cancer centre: UK experience. Eur J Oncol Nurs. 2004;8(Suppl 1):S54-S62.
21. Boyle D, Bubalo J. Enhancing patient adherence to improve outcomes with oral chemotherapy. Proceedings from a symposium at the 2007 Hematology/Oncology pharmacy association annual conference. US Pharm. 2007;32(10):1-8.
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
23. Kolb DA. Experiential learning. experience as the source of learning and development. Englewood Cliffs, New Jersey, US: Prentice-Hall; 1984.
24. Illeris K. What do we actually mean by experiential learning? Human Resource Development Review. 2007;6(1):84-95.
25. Candy PC. Reaffirming a proud tradition: Universities and lifelong learning. Active LearnHigher Educ. 2000;1(2):101-25.
26. Doan L. Virtual Pharmacogenomics Education: What works? [thesis]. Adelaide: University of South Australia; 2005.
27. Tran W. Establishing Learning Preferences: A Platform for Developing a Virtual Pharmacogenomics Breast Cancer Case Module [thesis]. Adelaide: University of South Australia; 2005.
28. Vark -A Guide to Learning Styles, Neil Fleming. http://www.vark-learn.com/english/index.asp. Accessed July 21, 2010.
29. Choy SO, Ng KC. Implementing wiki software for supplementing online learning. Australasian J Educ Technol. 2007;23(2):207-226.
30. Second Life FAQ - Frequently Asked Questions, Second Life. http://secondlife.com/whatis/faq.php. Accessed July 21, 2010.
31. Pharmatopia - a virtual island for real-world teaching, Monash University, Victoria, Australia. Available at: http://www.pharm.monash.edu.au/education/epharm/pharmatopia.html. Accessed July 21, 2010.
32. Carrington C, Gilbar P, Wintraaken J. SHPA standards of practice for the provision of oral chemotherapy for the treatment of cancer. J Pharm Pract Res. 2007;37(2):149-52.
33. Davis J, Harsley S, McLauchlan R, et al. SHPA standards of practice for the provision of clinical oncology pharmacy services: The Society of Hospital Pharmacists of Australia Committee of Specialty Practice in Oncology. J Pharm Pract Res. 2002;32(2): 115-8.
34. Content Outline for the Oncology Pharmacy Specialty Certification Examination, December 2006. Board of Pharmacy Specialties, Washington, United States. http://www.bpsweb.org/pdfs/content_outline_oncology.pdf. Accessed October 21, 2010.
35. Austin Z, Marini A, Croteau D, Violato C. Assessment of pharmacists' patient care competencies: validity evidence from Ontario (Canada)'s quality assurance and peer review process. Pharm Educ. 2004;4(1):23-32.